Abstract
Von Willebrand disease (VWD) is an inherited bleeding disorder that is caused by deficiency or dysfunction of Von Willebrand factor, a plasma protein that mediates the initial adhesion of platelets at sites of vascular injury and also binds and stabilizes blood clotting factor VIII in the circulation. VWD prevalence has been estimated in several countries on the basis of the number of symptomatic patients seen at haemostasis centers, and the values range from roughly 23 to 110 per million population. VWD is characterized by three key features: a personal history of excessive mucocutaneous bleeding, abnormal VWF laboratory studies, and evidence of a family history of the condition. Although bruising and epistaxis are common among children who have VWD, these symptoms also are reported in normal children. The accurate assessment of hemorrhagic symptoms is a key component in diagnosing VWD but this can present a significant challenge, particularly in the pediatric population. The challenges involved in making the diagnosis of Von Willebrand disease - focusing on personal bleeding history and the utility of bleeding questionnaires, along with family bleeding history and laboratory diagnosis in the pediatric population - will be reviewed.
Current Pediatric Reviews
Title: Diagnosis of Von Willebrand Disease in Children
Volume: 5 Issue: 3
Author(s): Nupur Mittal, Paula James and Leonard A. Valentino
Affiliation:
Abstract: Von Willebrand disease (VWD) is an inherited bleeding disorder that is caused by deficiency or dysfunction of Von Willebrand factor, a plasma protein that mediates the initial adhesion of platelets at sites of vascular injury and also binds and stabilizes blood clotting factor VIII in the circulation. VWD prevalence has been estimated in several countries on the basis of the number of symptomatic patients seen at haemostasis centers, and the values range from roughly 23 to 110 per million population. VWD is characterized by three key features: a personal history of excessive mucocutaneous bleeding, abnormal VWF laboratory studies, and evidence of a family history of the condition. Although bruising and epistaxis are common among children who have VWD, these symptoms also are reported in normal children. The accurate assessment of hemorrhagic symptoms is a key component in diagnosing VWD but this can present a significant challenge, particularly in the pediatric population. The challenges involved in making the diagnosis of Von Willebrand disease - focusing on personal bleeding history and the utility of bleeding questionnaires, along with family bleeding history and laboratory diagnosis in the pediatric population - will be reviewed.
Export Options
About this article
Cite this article as:
Mittal Nupur, James Paula and Valentino A. Leonard, Diagnosis of Von Willebrand Disease in Children, Current Pediatric Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339609789007213
DOI https://dx.doi.org/10.2174/157339609789007213 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials DNA Tetraplex-Binding Drugs Structure-Selective Targeting is Critical for Antitumour Telomerase Inhibition
Mini-Reviews in Medicinal Chemistry Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents
Recent Patents on Anti-Cancer Drug Discovery Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Role of Phase II Drug Metabolizing Enzymes in Cancer Chemoprevention
Current Drug Metabolism Prostate Cancer, miRNAs, Metallothioneins and Resistance to Cytostatic Drugs
Current Medicinal Chemistry Antifungal Therapy Used in Central Nervous System Fungal Infections
Central Nervous System Agents in Medicinal Chemistry EBV-Related Malignancies, Outcomes and Novel Prevention Strategies
Infectious Disorders - Drug Targets Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery PPARγ in Angiogenesis and Vascular Development
Current Angiogenesis (Discontinued) Umbilical Cord Tissue Mesenchymal Stem Cells: Characterization and Clinical Applications
Current Stem Cell Research & Therapy CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies
Current Drug Targets Drug Discovery in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Lifestyle Factors and MicroRNAs: A New Paradigm in Cancer Chemoprevention
MicroRNA Integrin Function and Signaling as Pharmacological Targets in Cardiovascular Diseases and in Cancer
Current Pharmaceutical Design The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Current Cancer Drug Targets Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors
Current Gene Therapy Hodgkin Lymphoma in HIV Positive Patients
Current HIV Research